Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer
Recruiting now
Conditions studied: Colo-rectal Cancer (dMMR/MSI-H CRC)
In brief
This study is a prospective, observational, real-world investigation. This study will evaluate the efficacy and safety of tislelizumab monotherapy before surgery in patients with mismatch repair deficient or microsatellite instability high (dMMR/MSI-H) locally advanced colorectal cancer. All patients will receive three cycles of tislelizumab neoadjuvant therapy followed by curative surgery. Postoperatively, based on surgical pathology, patients will receive adjuvant therapy with a regimen selected by the investigator or adopt a watch-and-wait strategy. The investigators will conduct a 5-year prospective follow-up. The investigators plan to enroll approximately 30 subjects.
Key facts
- Study ID
- NCT07352280
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- People needed
- 30
- Starts
- 2026-02-01
- Expected to finish
- 2032-12-31
- Last updated by the study team
- 2026-02-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years, ECOG performance status score 0-2.
- Pathologically confirmed stage II-III colorectal adenocarcinoma (according to AJCC 8th edition).
- Histologically confirmed mismatch repair deficient or genetic testing confirmed microsatellite instability high tumor.
- Signed written informed consent.
You may not qualify if…
- The patient has a history of other serious conditions rendering them unsuitable for surgery.
- Subjects with the following conditions: active autoimmune diseases, active infectious diseases, inflammatory bowel diseases; requiring long-term glucocorticoid or immunosuppressive therapy during treatment; history of immunodeficiency; history of organ transplantation or haematopoietic stem cell transplantation; severe interstitial pneumonia or pulmonary fibrosis.
- Known hypersensitivity to any component or excipient of tislelizumab or other PD-1/PD-L1 agents.
- Other conditions deemed unsuitable for inclusion by the investigator.
Where it is running
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences — Beijing, Undefined, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.